BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Diabetes mellitus
,
Endothelial cell
,
Anticancer prodrugs
,
Bleomycin
,
rs2230926
,
GATA1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
chloride channel protein
Summary
General Info
Curated Studies
Most Correlated Studies
Drug target sets for approved compounds
Drug Matrix In Vivo Toxicogenomic Study - Rat Kidney [Codelink]
Liver Pharmacology and Xenobiotic Response Repertoire
Drug Matrix In Vivo Toxicogenomic Study - Rat Liver [Codelink]
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
A complex CLCN1 variant associated with hereditary myotonia in a mixed-breed dog.
A pedigree of myotonia congenita with a novel mutation p.F343C of the CLCN1 gene].
Characterization of ClC-1 chloride channels in zebrafish: a new model to study myotonia.
ClC-1 Chloride Channel: Inputs on the Structure-Function Relationship of Myotonia Congenita-Causing …
Myotonia congenita in a Greek cohort: Genotype spectrum and impact of the CLCN1:c.501C > G variant a…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Block…
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type …
Clinical and Genetic Profile of Pediatric Patients With Cystic Fibrosis in Sohag.
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ